Osimertinib

CAS 1421373-65-0 0 current recordsSmall Molecule

Who holds supplier records for Osimertinib? No organisation holds a current US Type II DMF or EU CEP for Osimertinib in the registers PharmaTek covers.

Most records are filed under another form of this substance: Osimertinib Mesylate (6 current sources). A DMF or CEP is listed under the form it names.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Osimertinib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/osimertinib

Reading the evidence

  • No current DMF or CEP on record

    The covered registers hold no supplier record for this substance. This is not evidence that no one makes it: suppliers may file under another name, sell outside the US and EU, or use an ASMF.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Osimertinib expires 26 Nov 2042. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (0)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Osimertinib. Country is the organisation's recorded country, not necessarily the manufacturing site.

Not found in the covered registers (FDA DMF list, EDQM). This is not evidence that no supplier exists.

Need Osimertinib sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Osimertinib). The latest listed patent expires 26 Nov 2042. The latest listed exclusivity runs to 25 Sept 2031. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Osimertinib is a third-generation tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR) gene. It is designed to target both the initial activating EGFR mutations and the T790M resistance mutation.

Chemical identity

IUPAC name
N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide
Canonical SMILES
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
InChIKey
DUYJMQONPNNFPI-UHFFFAOYSA-N
Synonyms
Tagrisso API, azd-9291, azd-9291 free base, azd9291, mereletinib

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Kinase Inhibitor
Mechanism of action
Breast Cancer Resistance Protein Inhibitors; Cytochrome P450 1A2 Inducers; Cytochrome P450 3A Inhibitors; Cytochrome P450 3A4 Inducers; Kinase Inhibitors

Therapeutic areas

Oncology

Record history

PharmaTek records which organisations hold a current DMF or CEP for Osimertinib every week, starting 23 Oct 2026. Additions and lapses will appear here from the next weekly release.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Does the FDA Orange Book list patents for products containing Osimertinib?

Yes. The latest patent listed for an approved US product containing Osimertinib expires 26 Nov 2042, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Osimertinib supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Osimertinib?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.